Trade

Alivus Life Sciences share price

Balanced risk
  • 28%Low risk
  • 28%Moderate risk
  • 28%Balanced risk
  • 28%High risk
  • 28%Extreme risk
  • ₹870.70(-1.89%)
    January 16, 2026 15:29:58 PM IST
    • NSE
    • BSE
  • Vol : 41.75 K (NSE + BSE)
    Last 20 day avg : 48.64 K

Alivus Life Sciences is trading -1.89% lower at Rs 870.70 as compared to its last closing price. Alivus Life Sciences has been trading in the price range of 893.55 & 870.70. Alivus Life Sciences has given -3.05% in this year & -3.44% in the last 5 days. Alivus Life Sciences has TTM P/E ratio 21.44 as compared to the sector P/E of 22.69.There are 4 analysts who have initiated coverage on Alivus Life Sciences. There are 2 analysts who have given it a strong buy rating & 2 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of 130.03 Crores in its last quarter.Listed peers of Alivus Life Sciences include Cipla (-2.52%), Sun Pharmaceutical Industries (-1.84%), Divi's Laboratories (-1.93%).The Mutual Fund holding in Alivus Life Sciences was at 3.87% in 30 Sep 2025. The MF holding has decreased from the last quarter. The FII holding in Alivus Life Sciences was at 6.84% in 30 Sep 2025. The FII holding has increased from the last quarter.

  • Overview
  • Financials
  • Forecast
  • Technical Analysis
  • Peers
  • Shareholding
  • About the company
  • FAQ

Overview

  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • 6 M
  • 1 Y
  • 5 Y
  • MAX
Explore on
Loading...
Key Metrics

Updated on Jan 16, 2026, 10:57 PM UTC

  • Beta
    Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
    1.16
    High volatility
  • Debt To Equity
    The debt-to-equity ratio, indicating a company's financial leverage.
    0.02
    Lower than industry
  • Dividend Yield
    Annual dividends as a percentage of the stock price.
    0.56
    Lower than industry
  • PEG Ratio
    The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
    5.85
    Indicates overvaluation
  • P/E
    Price-to-earnings ratio based on trailing 12-month earnings
    -
  • P/B
    The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
    -
Price range
Day Range
Lowest
870.70
Highest
893.55
52 week range
Lowest
827.10
Highest
1,259.75
Alivus Life Sciences News
Alivus Life Sciences Peers
Return Comparison
Peers Comparison
Names
Technical ratingPrice%ChangeMarket CapP/EP/BDividend YieldDebt to Equity
Cipla
Bearish
1,398.45-2.521,12,922.4622.953.870.870.81
Sun Pharmaceutical Industries
Bearish
1,669.20-1.844,00,487.5636.245.770.920.50
Divi's Laboratories
Bearish
6,233.95-1.931,65,491.7978.6111.520.460.01
Torrent Pharmaceuticals
Bullish
4,018.750.351,36,007.3067.3217.10.8317.62
Dr Reddy's Laboratories
Bearish
1,175.65-0.9198,110.3818.633.140.632.34
Mutual Fund Ownership
View all
Quant Healthcare Fund Regular Growth
NA
  • Amount Invested (Cr.) 25.64
  • % of AUM 6.15
Quant Business Cycle Fund Regular Growth
NA
  • Amount Invested (Cr.) 51.79
  • % of AUM 3.90
Old Bridge Focused Equity Fund Regular Growth
NA
  • Amount Invested (Cr.) 37.14
  • % of AUM 2.14
Quant Flexi Cap Fund Growth
5/5
  • Amount Invested (Cr.) 113.28
  • % of AUM 1.58
Union Children's Fund Regular Growth
NA
  • Amount Invested (Cr.) 0.68
  • % of AUM 0.98
Alivus Life Sciences Corporate Actions
View all
  • Board Meetings
  • AGM
  • Dividends
  • Bonus
  • Split
  • Rights
Meeting DatePurpose
2026-01-22Quarterly Results
2025-11-06Quarterly Results
2025-08-01Quarterly Results
2025-05-15Audited Results & Final Dividend
2025-01-23Quarterly Results
About the company Alivus Life Sciences
  • IndustryBiotechnology & Drugs
  • ISININE03Q201024
  • BSE Code543322
  • NSE CodeALIVUS
Alivus Life Sciences Limited, formerly Glenmark Life Sciences Limited, is an India-based developer and manufacturer of non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas. The Company is providing contract development and manufacturing (CDMO) services to a range of multinational and specialty pharmaceutical companies. Its primary therapy areas include cardiovascular (CVS) disease, central nervous system (CNS) disorders, diabetes, oncology, pain management (anti-migraine, analgesic) and anti-infectives (antibiotic). It also develops APIs in the therapeutic areas such as antifungal, anti-histaminic, anti-acne, anti-emetic, ophthalmologic agent, urinary and anti-spasmodic. It has a diversified portfolio of around 151 molecules & supplies its products to customers in India, Europe, North America, Latin America, Japan and the rest of the world. Its four manufacturing facilities are located in Ankleshwar, Dahej, Mohol and Kurkumbh.
  • Management Info
  • Yasir RawjeeChief Executive Officer, Managing Director, Executive Director
  • Tushar MistryChief Financial Officer, Senior Vice President
  • Sumantra MitraSenior Vice President - Human Resources, Head - Human Resources
  • Navin AgrawalSenior Vice President - Quality, Head - Corporate Quality
  • Mathew GeorgeSenior Vice President - Regulatory Affairs, Head - Regulatory Affairs
  • Rudalf CorrieaCompany Secretary, Compliance Officer
  • Palle AcharyuluGroup Vice President, Head - Research and Development
  • Vinod NaikHead - Technical Operations, Whole Time Director
Alivus Life Sciences Share Price FAQs

Alivus Life Sciences is trading at 870.70 as on Fri Jan 16 2026 09:59:58. This is -1.89% lower as compared to its previous closing price of 887.45.

The market capitalization of Alivus Life Sciences is 10800.25 Cr as on Fri Jan 16 2026 09:59:58.

The average broker rating on Alivus Life Sciences is Strong Buy. The breakup of analyst rating is given below -

  • 2 analysts have given a strong buy rating
  • 2 analysts have given a buy rating
  • 0.00 analysts have given a hold rating
  • 0.00 analysts have given a sell rating
  • 0.00 analysts have given a strong sell rating

The 52 wk high for Alivus Life Sciences is 1259.75 whereas the 52 wk low is 827.10

Alivus Life Sciences can be analyzed on the following key metrics -

  • TTM P/E: 21.44
  • Sector P/E: 22.69
  • Dividend Yield: 0.56%
  • D/E ratio: 0.02

Alivus Life Sciences reported a net profit of 485.63 Cr in 2025.

The Mutual Fund Shareholding was 3.87% at the end of 30 Sep 2025.

Quick Links
EQUITY QUICK LINKS
Alivus Life Sciences QUICK LINKS
FROM MARKETS
RELATED LINKS
Quarterly Results
Business News/Market/Market Stats/  Alivus Life Sciences share price
✕

Wait for it…

Log in to our website to save your bookmarks. It'll just take a moment.

✕

Wait for it…

Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.